TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41079

Peptide_Name

Temporin-PKE-3K

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 17-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

FLPKIIGKLSSLLPKIF-NH2

FASTA

>TPDB41079|Anticancer|length=17
FLPKIIGKLSSLLPKIF-NH2

Formula C96H160N20O20

Absent Amino Acids ARNDCEQHMTWYV

Common Amino Acids L

Mass 1914.45

PI 10.84

Basic Residues 3

Acidic Residues 0

Hydrophobic Residues 9

Net Charge +3

Boman Index -1.29

Hydrophobicity 1.024

Aliphatic Index 160.59

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 2

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

1

G

0

H

3

I

4

L

3

K

0

M

2

F

2

P

2

S

0

T

0

W

0

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 4 K: 3 M: 0 F: 2 P: 2 S: 2 T: 0 W: 0 Y: 0 V: 0

Length

17

Formula

C96H160N20O20

Mass

1914.45

PI

10.84

Net Charge

+3

Boman Index

-1.29

Hydrophobicity

1.024

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 2.83 µM

Detail Source Activity Anticancer

Activity Measurement 2.83 µM

Target

Cancer Type Brain Tumor

Cell Line U251-MG

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 3.01 µM

Detail Source Activity Anticancer

Activity Measurement 3.01 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 0.51 µM

Detail Source Activity Anticancer

Activity Measurement 0.51 µM

Target

Cancer Type Lung Cancer

Cell Line H-838

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 0.38 µM

Detail Source Activity Anticancer

Activity Measurement 0.38 µM

Target

Cancer Type Colorectal Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 3.29 µM

Detail Source Activity Anticancer

Activity Measurement 3.29 µM

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2022